Emergent BioSolutions Posts $180M Q2 Loss on $191M NARCAN Impairment, Announces Restructuring to Save $40M
EBS is trading near its 52-week low of $5.87 (5.5% above the low).
Summary
Emergent BioSolutions reported a $180.2 million Q2 loss after a $191.3 million NARCAN impairment, and announced a restructuring to cut 93 jobs and save $40 million annually.
Key Events · Earnings and Guidance · EBS
-
NARCAN Impairment Drives $180M Loss
A $191.3 million non-cash impairment charge on the NARCAN intangible asset, reflecting lower pricing and sales volumes, pushed Q2 net loss to $180.2 million, or $3.49 per share.
-
Revenue Surges on MCM Products
Total revenue rose 66% to $234.3 million, led by a $109.6 million increase in MCM product sales, including ACAM2000 and BAT, partially offset by a 22% decline in Naloxone sales.
-
Restructuring to Cut 93 Jobs
The company announced a plan to reduce its workforce by 93 employees and eliminate 21 vacant positions, expecting $40 million in annualized savings, with $10–$11.5 million in charges in H2 2026.
-
Debt Refinancing and Cash Decline
Cash and equivalents fell to $139.7 million from $205.4 million at year-end 2025. The company refinanced its term loan, incurring a $20.5 million loss on extinguishment, and now has $581.8 million in total debt.
Analysis · EBS · Life Sciences
A $191.3 million non-cash impairment on the NARCAN intangible asset—reflecting deteriorating pricing and sales volumes for the naloxone product—drove Emergent BioSolutions to a dramatically wider Q2 net loss of $180.2 million. While revenue jumped 66% to $234.3 million on strong MCM product sales, the write-down and a $20.5 million loss on debt extinguishment overwhelmed the top-line gain. Cash reserves fell to $139.7 million from $205.4 million at year-end. Concurrently, the company announced a restructuring plan to cut 93 jobs and save $40 million annually, signaling a push to reduce costs and improve margins. The combination of a major asset impairment, declining cash, and a workforce reduction raises concerns about the sustainability of the commercial business and the company's ability to service its $581.8 million debt load.
At the time of this filing, EBS was trading at $6.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $389M. The 52-week trading range was $5.87 to $14.06. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.